Dani Baird and her family members carry a mutated Cu,Zn-superoxide dismutase-1 (SOD1) gene, one of thirteen genes suspected of causing motor neuron diseases (MNDs). According to the National…
Different types of movement disorders are difficult to distinguish due to many patients experiencing similar symptoms. Stephen Stahl, MD, discusses the differences between movement disorders, how they might…
PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain.
While there are not yet any standardized criteria for selecting candidates for deep brain stimulation (DBS) therapy, Kelvin L. Chou, MD, Co-Director of the STIM (Surgical Therapies Improving…
As patients begin displaying symptoms of Parkinson’s disease, it becomes increasingly difficult for them to express themselves verbally, and they may even become overwhelmed in loud social situations.…
Results from a retrospective study in Lancet Neurology reveal that high concentrations of neurofilament light proteins (NfLs) in blood plasma of HTT gene mutation carriers can predict clinical…
Professor Peter Jennings, BPharm, PhD, DSc, at Kings College of London discussed the most promising treatments out there right now for combating Parkinson’s. He discussed the condition to…
Deutetrabenazine, a novel VMAT-2 inhibitor, was evaluated in phase 3 trials for the treatment of tardive dyskinesia. The deuterated form of tetrabenazine was found to be well-tolerated, safe,…
Those who are living with Parkinson’s disease or have a loved one who has PD will tell you how mentally and physically debilitating the illness can be. A…